CN102670493A - Lomefloxacin hydrochloride eye drops and preparation method and application thereof - Google Patents
Lomefloxacin hydrochloride eye drops and preparation method and application thereof Download PDFInfo
- Publication number
- CN102670493A CN102670493A CN2012101590651A CN201210159065A CN102670493A CN 102670493 A CN102670493 A CN 102670493A CN 2012101590651 A CN2012101590651 A CN 2012101590651A CN 201210159065 A CN201210159065 A CN 201210159065A CN 102670493 A CN102670493 A CN 102670493A
- Authority
- CN
- China
- Prior art keywords
- sodium
- eye drop
- lomefloxacin
- lomefloxacin hydrochloride
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses lomefloxacin hydrochloride eye drops and a preparation method and application thereof. The lomefloxacin accounts for 0.3% of the active components. The preparation also comprises a tackifier, a buffer salt system, a wetting agent, an isoosmotic adjusting agent, a pH adjusting agent and a bacteriostatic agent, and is suitable for treating the external eye infections such as acute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomiantis, dacryocystitis, keratitis, keratohelcosis and the like caused by sensitive pathogenic bacteria. The product is characterized in that: by adding the sodium hyaluronate with a tackifying effect and a moisturizing effect, the viscosity of the lomefloxacin hydrochloride eye drops is improved, the fluidics property thereof is changed, the residence time of the eye drops in the eyes is prolonged, the sufficient absorption of the medicine is ensured, the bioavailability is increased, the administration times are reduced, the compliance of a patient is improved, and an effective treatment effect is realized.
Description
Technical field
The present invention relates to a kind of opthalmological preparation of field of medicaments, be specifically related to prescription of a kind of lomefloxacin hydrochloride eye drop that can be used for treating outer eyes infection such as responsive cause a disease microbial acute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomitis, dacryocystisis, keratitis and corneal ulcer etc. and preparation method thereof.
Background technology
Lomefloxacin (lomefloxacin) is a third generation quinolones broad spectrum antibiotic, and its mechanism of action is for suppressing the DNA of bacteria helicase.Gram negative bacteria, positive bacteria and part anaerobe all there is antibacterial activity.Lomefloxacin hydrochloride (lomefloxacin Hydrochloric acid) is the hydrochlorate of lomefloxacin, and its capsule, tablet, eye drop, ear drop, injection etc. are arranged clinically, is used for the treatment of the microbial bacterial infection of various sensitivities.No matter antibacterial is in active phase or all can be killed effectively resting stage, external and clinical application effect shows that this medicine is a spectrum, efficient, safe antibiotics.
The lomefloxacin hydrochloride eye drop is used for outer eye infection such as treatment responsive cause a disease microbial acute and chronic bacterial conjunctivitis, blepharitis, hordeolum, meibomitis, dacryocystisis, keratitis and corneal ulcer etc. at present.Lomefloxacin hydrochloride eye drop treatment ocular infection is carried out more research abroad, obtained gratifying effect.Bibliographical information; Because this medicine penetrance is good; During local application; Preceding aqueous humor Chinese medicine concentration is higher, and ocular infection property diseases such as bacterial conjunctivitis, bacterial keratitis, chronic dacryocystitis, hordeolum, blepharitis are all had comparatively ideal therapeutic effect, and bacteria culture media MIC result of the test page or leaf shows that this medicine has stronger killing action to the several extremely greatly pathogenic bacterium of eye.
But because this preparation is the aqueous solution of lomefloxacin hydrochloride, viscosity is low excessively, most of fluid loss behind the eye drip; Loss is serious, if nictation, then loss was more serious, bioavailability is low; In order to reach effective drug level; Need multiple dosing, make that patient's compliance is low, influence therapeutic effect.
In addition, because lomefloxacin hydrochloride is mildly bitter flavor, make behind the eye drop behind the eye drip, medicinal liquid can flow in the nose through tear stains, thereby makes the bitter taste sense of medicine, and the patient is not felt well.
To the defective of above-mentioned lomefloxacin hydrochloride eye drop, the present invention increases the medicinal liquid viscosity through changing lomefloxacin hydrochloride eye drop fluidics character; Prolong medicinal liquid in the eye holdup time, medicine is fully absorbed, thereby improve bioavailability; Reduce the medication number of times; Reduce patient's sense of discomfort, improve patient's compliance, reach effective therapeutic effect.
Summary of the invention
Learn character according to liquid fluid, to active component of the present invention, the present invention has the tackifier of adhesion-promoting effect and moisture-keeping function, the sour sodium of preferred glass through adding; Select suitable adjuvant simultaneously, improve the viscosity of lomefloxacin hydrochloride eye drop, its fluidics character is changed, prolong medicinal liquid in the eye holdup time; Guarantee that medicine fully absorbs, improve bioavailability, reduce the medication number of times; Reduce simultaneously zest greatly, improve patient's compliance, reach therapeutic effect effectively.
The object of the invention provides a kind of lomefloxacin hydrochloride eye drop
Another purpose of the present invention provides a kind of lomefloxacin hydrochloride eye drop method for preparing.
A kind of lomefloxacin hydrochloride eye drop; It comprises; Calculate by weight; As the 0.3-0.5% lomefloxacin or the husky star of hydrochloric acid Lip river magnesium of active component, 0.03-0.1% tackifier, 0.1-0.3% wetting agent, 0.01-0.03% buffer salt system, 0.4-0.7% osmotic pressure regulator, 0.01-0.03% antibacterial, 98.5-99% water for injection.
Also contain the PH regulator in the lomefloxacin hydrochloride eye drop of the present invention, it is a sodium hydroxide test solution, regulates eye drop pH to 6.0.
Described tackifier is a kind of, two or more mixture in hyaluronic acid sodium, hydroxypropyl emthylcellulose, methylcellulose, carmethose, Na-alginate and the carbomer, special preferred glass acid sodium.
Described buffer comprises a kind of, two or more mixture in sodium dihydrogen phosphate-sodium hydrogen phosphate, boric acid-Borax, acetic acid-ammonium acetate, acetic acid-sodium-acetate buffer and the citrate buffer, special preferably phosphoric acid sodium dihydrogen-sodium hydrogen phosphate.
Described wetting agent is a kind of, two or more mixture in glycerol, Polyethylene Glycol and the poloxamer.
Described osmotic pressure regulator is a kind of, two or more mixture in sodium chloride, mannitol, sodium lactate and the glucose, preferred especially sodium chloride;
Antibacterial is a kind of, two or more mixture in benzalkonium bromide, benzalkonium chloride, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, butyl hydroxybenzoate, phenylpropanol, sorbitol and the thimerosal, preferred especially benzalkonium bromide.
The preferred lomefloxacin hydrochloride eye drop of the present invention is characterized in that lomefloxacin or lomefloxacin hydrochloride are 0.3%, and hyaluronic acid sodium is 0.04%; Sodium dihydrogen phosphate-sodium hydrogen phosphate is 0.02%; Glycerol is 0.2%, and sodium chloride is 0.48%, and benzalkonium bromide is 0.02%; Sodium hydroxide is an amount of, and surplus is a water for injection.
The method for preparing of lomefloxacin hydrochloride eye drop of the present invention is:
(1) with the tackifier of recipe quantity, preferred glass acid sodium is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) principal agent lomefloxacin or the lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; Add buffer salt system, osmotic pressure regulator, antibacterial, the wetting agent of recipe quantity, after mixing, change over to again in (1); Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Maximum characteristics of the present invention are to active component of the present invention, and selecting with ubiquitous acidic mucopolysaccharide hyaluronic acid sodium (Hyaluronan) in the organism is tackifier, and its aqueous solution has excellent biological compatibility, high viscosity elasticity; Be a kind of non-Newton fluid characteristic and false plasticity, permeability, cooperate with some specific adjuvants simultaneously, mix with medicinal liquid; Can improve the fluidics character of medicine, make eye drop have high viscosity elasticity, prolong the medicinal liquid eye holdup time; Improve bioavailability, and through the comfort behind the lubrication increase eye drip, thereby the medication number of times reduced; Improve patient's compliance, guarantee effectively treatment.
Description of drawings
Fig. 1 tear medicine time graph
Fig. 2 aqueous humor pharmaceutical concentration-time curve
The specific embodiment
Further specify the present invention through embodiment below.The method for preparing that it should be understood that the embodiment of the invention is only used for explaining the present invention, rather than limitation of the present invention.
Embodiment 1
Prescription:
Its preparation method is:
(1) hyaluronic acid sodium with recipe quantity is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) the principal agent lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; The mixed solution of the sodium dihydrogen phosphate-sodium hydrogen phosphate buffer of adding recipe quantity, sodium chloride, benzalkonium bromide, glycerol after mixing, changes in (1) again; Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Embodiment 2
Prescription:
Its preparation method is:
(1) hyaluronic acid sodium with recipe quantity is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) the principal agent lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; The mixed solution of the sodium dihydrogen phosphate-sodium hydrogen phosphate of adding recipe quantity, sodium chloride, benzalkonium bromide, glycerol after mixing, changes in (1) again; Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Embodiment 3
Prescription:
Its preparation method is:
(1) hyaluronic acid sodium with recipe quantity is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) the principal agent lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; The mixed solution of the sodium dihydrogen phosphate-sodium hydrogen phosphate of adding recipe quantity, sodium chloride, benzalkonium chloride, glycerol after mixing, changes in (1) again; Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Comparative Examples 1
Prescription:
Its preparation method is:
The principal agent lomefloxacin hydrochloride of recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; The mixed solution of the phosphate sodium dihydrogen buffer solution of adding recipe quantity, sodium chloride, benzalkonium chloride, glycerol; After mixing, regulate pH to 6.0, add the full dose of injecting water with the 0.1mol/L sodium hydroxide solution; With 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Comparative Examples 2
Prescription:
Its preparation method is:
(1) hydroxypropyl emthylcellulose with recipe quantity is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) the principal agent lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; The mixed solution of the boric acid of adding recipe quantity, Borax, sodium chloride, benzalkonium chloride, glycerol after mixing, changes in (1) again; Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Comparative Examples 3
Prescription:
Its preparation method is:
(1) hydroxyl third methylcellulose with recipe quantity is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) the principal agent lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; The mixed solution of the sodium dihydrogen phosphate/sodium hydrogen phosphate of adding recipe quantity, sodium chloride, benzalkonium chloride, glycerol after mixing, changes in (1) again; Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Comparative research
One, stability relatively
Get embodiment 1～4 and Comparative Examples 1～3 assembly side and commercially available article, commercially available back is in 40 ℃; Relative humidity 65% condition held 6 months; Take a sample respectively 1st month, 2 months, 3 months, 6 the end of month and once to detect, and compare with 0 month result, result of the test is seen table 1.
Table 1 lomefloxacin hydrochloride eye drop enforcement group and matched group accelerated stability are investigated the result
Two, irritation test relatively
Get the embodiment of the invention, Comparative Examples and blank adjuvant, observe behind the animal eyes contact test sample IR situation conjunctiva, cornea and iris.
(cornea does not have muddiness, and conjunctiva does not have hyperemia, edema and secretions, and pupil is circular to get 21 of the undamaged healthy rabbits of examination of eyes; Both sides etc. are big, and light reflex is good), be divided into 7 groups at random by body weight; 3/group, the 1st group of left eye made own control to normal saline, and right eye is given blank adjuvant eye drop.The 2nd～7 group of left eye also made own control to normal saline, and right eye is given embodiment 1～3 and Comparative Examples 1～3.Respectively with medicine liquid droplet in tame lagophthalmos conjunctival sac, the compressing nasolacrimal duct and made the passive closure of eyes about 5～10 seconds.4 times/day, each 1～2 (about 50ul), eye drip is 14 days continuously; Before each administration and after the last administration 1,2,4,24,48 and 72 hour, directly perusal or observe cornea, iris, conjunctiva with magnifier and whether zest is arranged, and zest is marked; Whether in good time with the dyeing of 2% fluorescein sodium, observing each position has paintedly, and the result carries out IR by table 1 and marks; The IR score value addition of cornea, iris and conjunctiva of each rabbit gets total mark observing time with each; One group integration summation divided by number of animals, is promptly got last mean scores, and compare with left eye.Then, press the evaluation criterion judgement sample to eye irritation.When the stimulus intensity of cornea, iris, conjunctiva is inconsistent, should make evaluation respectively.All observations finish the back and put to death rabbit, and the clip eyes reach goes up palpebra inferior, and perusal has or not ANOMALOUS VARIATIONS such as redness, and are fixing in 10% formalin then, FFPE, and section, histopathological examination is carried out in HF dyeing.
Eye IR score value standard
The eye irritation evaluation criterion
| Score value | 0-3 | 4-8 | 9-12 | 13-16 |
| Estimate | Nonirritant | Slight zest | The moderate zest | The intensity zest |
Zest result sees table 2.
Table 2 levofloxacin eye drop irritation test result
Can know through stability study, all up to specification to the embodiment of the invention and Comparative Examples outward appearance, content, pH, related substance, but embodiment group viscosity is big and stable, and the determination data of total related substance shows that the embodiment group is being superior to Comparative Examples in varying degrees.
The result can know through animal eye irritation test, and Comparative Examples 1,2,3 has slight zest, and embodiment 1,2,3, blank adjuvant and normal saline are all non-stimulated, and lomefloxacin hydrochloride eye drop nonirritant provided by the present invention is described.
Three, pharmacokinetic study
Describe the preparation sample with embodiment 1-3 and Comparative Examples 1-3, investigated its lagophthalmos anterior chamber pharmaco-kinetic processes of being in separately respectively, result of the test is seen Fig. 1-Fig. 2.
Conclusion: lomefloxacin hydrochloride eye drop provided by the present invention has good stability, and to the eye nonirritant, makes eye drop have high viscosity elasticity; Can prolong the medicinal liquid eye holdup time; Improve bioavailability, and through the comfort behind the lubrication increase eye drip, thereby the medication number of times reduced; Improve patient's compliance, guarantee effectively treatment.
Claims (8)
1. lomefloxacin hydrochloride eye drop; It comprises; Calculate by weight; As the 0.3-0.5% lomefloxacin or the husky star of hydrochloric acid Lip river magnesium of active component, 0.03-0.1% tackifier, 0.1-0.3% wetting agent, 0.01-0.03% buffer salt system, 0.4-0.7% osmotic pressure regulator, 0.01-0.03% antibacterial, 98.5-99% water for injection.
2. eye drop according to claim 1; It is characterized in that tackifier is a kind of, two or more mixture in hyaluronic acid sodium, hydroxypropyl emthylcellulose, methylcellulose, carmethose, Na-alginate and the carbomer, special preferred glass acid sodium.
3. eye drop according to claim 2; It is characterized in that buffer comprises a kind of, two or more mixture in sodium dihydrogen phosphate-sodium hydrogen phosphate, boric acid-Borax, acetic acid-ammonium acetate, acetic acid-sodium-acetate buffer and the citrate buffer, special preferably phosphoric acid sodium dihydrogen-sodium hydrogen phosphate.
4. eye drop according to claim 3 is characterized in that wetting agent is a kind of, two or more mixture in glycerol, Polyethylene Glycol and the poloxamer, special preferably glycerine.
5. eye drop according to claim 4 is characterized in that osmotic pressure regulator is a kind of, two or more mixture in sodium chloride, mannitol, sodium lactate and the glucose, preferred especially sodium chloride.
6. eye drop according to claim 5 is characterized in that the pH regulator agent is a sodium hydroxide test solution; Antibacterial is a kind of, two or more mixture in benzalkonium bromide, benzalkonium chloride, methyl hydroxybenzoate, ethyl hydroxybenzoate, propyl hydroxybenzoate, butyl hydroxybenzoate, phenylpropanol, sorbitol and the thimerosal, preferred especially benzalkonium bromide.
7. according to the said eye drop of claim 1, it is characterized in that lomefloxacin or lomefloxacin hydrochloride are 0.3%, hyaluronic acid sodium is 0.04%; Sodium dihydrogen phosphate-sodium hydrogen phosphate is 0.02%; Glycerol is 0.2%, and sodium chloride is 0.48%, and benzalkonium bromide is 0.02%; Sodium hydroxide is an amount of, and surplus is a water for injection.
8. according to the said eye drop of claim 1～6, it is characterized in that method for preparing is:
(1) with the tackifier of recipe quantity, preferred glass acid sodium is scattered in an amount of 40 ℃～55 ℃ waters for injection, makes swelling, processes clear solution;
(2) principal agent lomefloxacin or the lomefloxacin hydrochloride with recipe quantity is dissolved in an amount of 60 ℃～70 ℃ waters for injection; Add buffer salt system, osmotic pressure regulator, antibacterial, the wetting agent of recipe quantity, after mixing, change over to again in (1); Regulate pH to 6.0 with the 0.1mol/L sodium hydroxide solution; Add the full dose of injecting water, with 0.22 μ m filtering with microporous membrane, sterile packaged promptly gets after the passed examination.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210159065 CN102670493B (en) | 2012-05-22 | 2012-05-22 | Lomefloxacin hydrochloride eye drops and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210159065 CN102670493B (en) | 2012-05-22 | 2012-05-22 | Lomefloxacin hydrochloride eye drops and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102670493A true CN102670493A (en) | 2012-09-19 |
| CN102670493B CN102670493B (en) | 2013-09-18 |
Family
ID=46803492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210159065 Active CN102670493B (en) | 2012-05-22 | 2012-05-22 | Lomefloxacin hydrochloride eye drops and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102670493B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491876A (en) * | 2014-12-23 | 2015-04-08 | 中国药科大学 | Sodium hyaluronate-containing epinastine eye drops and preparation method thereof |
| CN105476954A (en) * | 2015-11-30 | 2016-04-13 | 湖北兴华制药有限公司 | Lomefloxacin hydrochloride injection and preparation method thereof |
| CN109833294A (en) * | 2019-04-19 | 2019-06-04 | 江苏远恒药业有限公司 | A kind of Lomefloxacin Hydrochloride Eye-drops and its preparation process |
| CN111700912A (en) * | 2020-06-03 | 2020-09-25 | 青岛海尔生物科技有限公司 | Eye drops suitable for limbal stem cell deficiency and preparation |
| CN115337263A (en) * | 2022-08-09 | 2022-11-15 | 江苏汉晨药业有限公司 | Lomefloxacin hydrochloride eye drops |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1459291A (en) * | 2003-05-28 | 2003-12-03 | 凌沛学 | Eyedrops containing low molecular weight heparin, and its prepn. method |
| CN1483478A (en) * | 2003-08-02 | 2004-03-24 | 无锡杰西医药科技有限公司 | Eye preparation formula adapted for therapentic medicine |
| CN1488404A (en) * | 2003-06-19 | 2004-04-14 | 刘继东 | Compounding use of sodium hyaluronate for eye preparation |
| CN1895253A (en) * | 2005-07-11 | 2007-01-17 | 张宏业 | Lomesaline hydrochloride eye drops and preparation thereof |
-
2012
- 2012-05-22 CN CN 201210159065 patent/CN102670493B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1459291A (en) * | 2003-05-28 | 2003-12-03 | 凌沛学 | Eyedrops containing low molecular weight heparin, and its prepn. method |
| CN1488404A (en) * | 2003-06-19 | 2004-04-14 | 刘继东 | Compounding use of sodium hyaluronate for eye preparation |
| CN1483478A (en) * | 2003-08-02 | 2004-03-24 | 无锡杰西医药科技有限公司 | Eye preparation formula adapted for therapentic medicine |
| CN1895253A (en) * | 2005-07-11 | 2007-01-17 | 张宏业 | Lomesaline hydrochloride eye drops and preparation thereof |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104491876A (en) * | 2014-12-23 | 2015-04-08 | 中国药科大学 | Sodium hyaluronate-containing epinastine eye drops and preparation method thereof |
| CN105476954A (en) * | 2015-11-30 | 2016-04-13 | 湖北兴华制药有限公司 | Lomefloxacin hydrochloride injection and preparation method thereof |
| CN109833294A (en) * | 2019-04-19 | 2019-06-04 | 江苏远恒药业有限公司 | A kind of Lomefloxacin Hydrochloride Eye-drops and its preparation process |
| CN111700912A (en) * | 2020-06-03 | 2020-09-25 | 青岛海尔生物科技有限公司 | Eye drops suitable for limbal stem cell deficiency and preparation |
| CN111700912B (en) * | 2020-06-03 | 2022-04-19 | 青岛海尔生物科技有限公司 | Eye drops suitable for limbal stem cell deficiency and preparation |
| CN115337263A (en) * | 2022-08-09 | 2022-11-15 | 江苏汉晨药业有限公司 | Lomefloxacin hydrochloride eye drops |
| CN115337263B (en) * | 2022-08-09 | 2023-10-03 | 江苏汉晨药业有限公司 | Lomefloxacin hydrochloride eye drops |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102670493B (en) | 2013-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102670494B (en) | Eye drop and preparation method and application thereof | |
| CN102670493B (en) | Lomefloxacin hydrochloride eye drops and preparation method and application thereof | |
| CN101129385B (en) | Ophthalmic composition containing gatifloxacin and lotepredenol etabonate and method of preparing the same | |
| CN102078284A (en) | Gatifloxacin-containing gel for eyes and preparation method thereof | |
| CN106913518A (en) | A kind of precursor type non-steroidal anti-inflammatory gel for eye use and preparation method thereof | |
| CN101130083B (en) | Ophthalmic composition, producing method and use of the same | |
| CN101278905A (en) | Ophthalmic composition containing natamycin, use and preparation method thereof | |
| CN101278908B (en) | Eye drop capable of significantly increasing medicament effect | |
| CN106880590A (en) | A kind of precursor type non-steroidal anti-inflammatory eye drops and preparation method thereof | |
| CN101926762B (en) | Rupatadine fumarate eye drops and preparation method thereof | |
| CN113662914A (en) | Eye gel containing voriconazole and preparation method and application thereof | |
| CN103565734B (en) | Bendazac lysine eye drops as well as preparation method thereof | |
| CN101797223B (en) | Huperzine A preparations for eyes and application thereof | |
| CN104606666B (en) | BFGF bovine basic fibroblast growth factor eye drop | |
| CN100584332C (en) | Eye-drops preparations containing tetrandrine and its application for preparing medicine therewith | |
| CN105213418A (en) | Preoperative compound eye drops of a kind of ophthalmology and preparation method thereof | |
| CN110812323B (en) | Ophthalmic composition, preparation method and application thereof | |
| CN100569218C (en) | Benzydalysine eye drop and preparation method thereof | |
| CN103705449B (en) | A kind of Uliflourxacin eye drop and preparation method thereof | |
| CN109453151B (en) | Pharmaceutical composition for eyes, preparation method and application thereof | |
| CN103735499B (en) | A kind of Ulifloxacin hydrochloride eye drop and preparation method thereof | |
| CN113786380A (en) | Pilocarpine nitrate ophthalmic gel and preparation method thereof | |
| CN110200904B (en) | Intraocular pressure reducing sustained-release eye drop composition and preparation method thereof | |
| CN100408046C (en) | Macrolide antibiotics sodium hyaluronate eye transfer system | |
| CN102512362B (en) | Formula and preparation method of compound ciprofloxacin eye drops |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 750002 the Ningxia Hui Autonomous Region street, Jinfeng District, Yinchuan City Fu Ning Lane No. 57 Patentee after: Ningxia Kang Ya pharmaceutical Limited by Share Ltd Address before: 750002 No. 6 road, hi tech Industrial Development Zone, the Ningxia Hui Autonomous Region, Yinchuan Patentee before: Kangya Pharmaceutical Industry Co., Ltd., Ningxia |